STAT1 and rheumatoid arthritis: The results of this pilot study suggest that, with a decrease in monocyte frequency, the baseline cytokine (mostly IFNα)-induced phosphorylation of STAT1 could represent an early predictor of treatment response in RA patients starting baricitinib.